VERACYTE INC (VCYT) Stock Price, Quote, News and Overview
NASDAQ:VCYT - Nasdaq - US92337F1075 - Common Stock - Currency: USD
VCYT Quote, Performance and Key Statistics
NASDAQ:VCYT (3/6/2025, 2:09:41 PM)
32.21
-0.75 (-2.28%)
The current stock price of VCYT is 32.21 USD. In the past month the price decreased by -24.66%. In the past year, price increased by 45.07%.
VCYT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.79 | 371.82B | ||
| AMGN | AMGEN INC | 15.96 | 169.87B | ||
| GILD | GILEAD SCIENCES INC | 25.05 | 143.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1671.69 | 124.54B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.23 | 75.99B | ||
| ARGX | ARGENX SE - ADR | 239.02 | 37.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.89B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.76B | ||
| BIIB | BIOGEN INC | 8.85 | 21.25B | ||
| NTRA | NATERA INC | N/A | 18.83B | ||
| GMAB | GENMAB A/S -SP ADR | 25.03 | 15.10B |
Related stock screener links
About VCYT
Company Profile
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 815 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and assure patients. The firm offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The firm also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Company Info
VERACYTE INC
6000 Shoreline Court, Suite 300
South San Francisco CALIFORNIA 94080 US
CEO: Bonnie H. Anderson
Employees: 815
Company Website: https://www.veracyte.com/
Investor Relations: https://investor.veracyte.com/
Phone: 16502436300
VERACYTE INC / VCYT FAQ
What is the stock price of VERACYTE INC today?
The current stock price of VCYT is 32.21 USD. The price decreased by -2.28% in the last trading session.
What is the ticker symbol for VERACYTE INC stock?
The exchange symbol of VERACYTE INC is VCYT and it is listed on the Nasdaq exchange.
On which exchange is VCYT stock listed?
VCYT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERACYTE INC stock?
18 analysts have analysed VCYT and the average price target is 47.23 USD. This implies a price increase of 46.62% is expected in the next year compared to the current price of 32.21. Check the VERACYTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERACYTE INC worth?
VERACYTE INC (VCYT) has a market capitalization of 2.50B USD. This makes VCYT a Mid Cap stock.
How many employees does VERACYTE INC have?
VERACYTE INC (VCYT) currently has 815 employees.
What are the support and resistance levels for VERACYTE INC (VCYT) stock?
VERACYTE INC (VCYT) has a support level at 32.95 and a resistance level at 38.73. Check the full technical report for a detailed analysis of VCYT support and resistance levels.
Is VERACYTE INC (VCYT) expected to grow?
The Revenue of VERACYTE INC (VCYT) is expected to grow by 10.11% in the next year. Check the estimates tab for more information on the VCYT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERACYTE INC (VCYT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VCYT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VCYT, evaluating the profitability, health, valuation and growth aspects
- VERACYTE INC (VCYT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERACYTE INC (VCYT) Sales and EPS estimates to see what analysts future expectations are.
- VERACYTE INC (VCYT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERACYTE INC (VCYT) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERACYTE INC (VCYT) Stock Chart to make your own analysis
- VERACYTE INC (VCYT) Latest news and press-releases to stay up to date.
Does VERACYTE INC (VCYT) stock pay dividends?
VCYT does not pay a dividend.
When does VERACYTE INC (VCYT) report earnings?
VERACYTE INC (VCYT) will report earnings on 2025-05-05, after the market close.
What is the Price/Earnings (PE) ratio of VERACYTE INC (VCYT)?
The PE ratio for VERACYTE INC (VCYT) is 107.37. This is based on the reported non-GAAP earnings per share of 0.3 and the current share price of 32.21 USD. Check the full fundamental report for a full analysis of the valuation metrics for VCYT.
What is the Short Interest ratio of VERACYTE INC (VCYT) stock?
The outstanding short interest for VERACYTE INC (VCYT) is 4.07% of its float. Check the ownership tab for more information on the VCYT short interest.
VCYT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VCYT. When comparing the yearly performance of all stocks, VCYT is one of the better performing stocks in the market, outperforming 82.8% of all stocks.
VCYT Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to VCYT. VCYT has an excellent financial health rating, but there are some minor concerns on its profitability.
VCYT Financial Highlights
Over the last trailing twelve months VCYT reported a non-GAAP Earnings per Share(EPS) of 0.3. The EPS increased by 129.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.41% | ||
| ROA | 1.86% | ||
| ROE | 2.05% | ||
| Debt/Equity | 0 |
VCYT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to VCYT. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 83.17% and a revenue growth 10.11% for VCYT